Abstract
Current guidelines recommend caution in prescribing concomitant use of direct-acting oral anticoagulants (DOACs) and antiepileptic drugs due to drug–drug interactions leading to potential risk of DOACs subtherapeutic concentration and treatment failure. Herein we report a significant interaction between carbamazepine (CZP) and apixaban, causing subtherapeutic concentration of the drug in a patient with atrial fibrillation who had a transient ischemic attack (TIA) episode. Another anti-Xa DOAC, edoxaban, administered to the patient after TIA occurrence did not show significant interaction with CZP. In addition to confirm that cautions should be used when antiepileptic and DOACs are concomitantly prescribed, the present case also demonstrates that, in the management of certain subsets of patients who need anticoagulant treatment, measurement of DOAC plasma concentration can help guide a personalized management and avoid adverse clinical outcomes.
Lingua originale | English |
---|---|
pagine (da-a) | 528-531 |
Numero di pagine | 4 |
Rivista | Journal of Thrombosis and Thrombolysis |
Volume | 48 |
DOI | |
Stato di pubblicazione | Pubblicato - 2019 |
Keywords
- Anti-Xa activity
- Anticonvulsants
- Atrial Fibrillation
- Carbamazepin
- Carbamazepine
- DOAC interaction
- Direct oral anticoagulant
- Drug Interactions
- Drug Monitoring
- Factor Xa Inhibitors
- Humans
- Ischemic Attack, Transient
- Personalized oral anticoagulant therapy
- Precision Medicine
- Pyrazoles
- Pyridines
- Pyridones
- Thiazoles